I'm coming off a stomach bug that took the whole house down for three days, so the timing on this one is almost cruel.
You look like a leaf that's been through the wash.
That's the nicest thing you've said to me all week. Daniel wrote in with a medical question for you, our resident retired pediatrician, and I want to get the disclaimer out of the way first, because he asked for it and because he's right. Nothing on this podcast is medical advice. If you're in this situation, get medically evaluated.
Agreed, and I'll say it once more at the end.
Daniel's premise is that there are two flavors of misery. The first is when you can't stop throwing up. The second, and he thinks this one is worse, is the lingering queasiness in the pit of your stomach that simply won't budge. He says anything is relief. And when vomiting isn't productive, doctors often tackle both things with one stone.
That's a good phrase.
His specifics. Gallbladder removed eight years ago, functional dyspepsia, postprandial distress, abdominophrenic dyssynergia. The surgery changed how his body handles alcohol, so he rarely goes past a couple of glasses of wine. Early on after the surgery, drinking meant getting profoundly sick with a lot of bile coming up.
That tracks.
He notes that functional dyspepsia treatment is spotty and partial, so old-school psychiatric meds get used off-label at low doses. Low-dose sulpiride is the one commonly reached for in Israel, which he points out isn't so routine elsewhere. It didn't do much for his bloating and caused brutal next-day fatigue, even below psychiatric dosing. But when nothing else cut through the queasy nausea, sulpiride did the trick.
That's a very precise observation.
His core question, then. What does the dopamine system have to do with nausea, and why does antagonizing it seem to work? He takes Vyvanse daily for ADHD and has never noticed nausea from it, despite it also acting on dopamine. He knows dopamine has subtypes and exists in the brain and the body, but he wants the connection to nausea and vomiting specifically. And finally, these anti-nausea meds are often contraindicated for long-term use. For people who really struggle with nausea, that's debilitating. So are there drugs developed to avoid the next-day fatigue or the risk profiles of the acute-use ones?
That's four questions stacked into one, and they're all good.
So let's start with the part of the brain that's actually doing the vomiting math.
The structure is the area postrema, also called the chemoreceptor trigger zone. It sits at the base of the fourth ventricle, and it has one feature that explains almost everything we're about to discuss. It's one of the few regions of the brain that sits outside the blood-brain barrier.
Which means it's tasting the blood.
Constantly. It samples blood and cerebrospinal fluid for toxins, drugs, metabolic signals. It's the brain's early-warning system for "something got into the body that shouldn't have." And it's densely packed with receptors that can trigger nausea and vomiting. Dopamine D2, serotonin 5-HT3, muscarinic M3, histamine H1, neurokinin NK1, GLP-1.
That's a lot of ways to make someone sick.
It's a detector with redundant wiring, which makes sense. If your job is to catch poison before it kills the organism, you don't want a single point of failure.
And dopamine is one of the signals it listens for.
Dopamine is one of the endogenous neurotransmitters acting on the CTZ. When dopamine stimulates D2 receptors in the area postrema, it signals the vomiting center, the dorsal vagal complex and nucleus tractus solitarius, to initiate nausea and the vomiting reflex. Block the D2 receptors there, and you've removed that trigger. That's why dopamine antagonists are antiemetics. They were the first class of antiemetics ever used.
Before anything else? There's a nuance I want to flag early, because it matters for Daniel's question about lingering queasiness. Nausea and vomiting are not the same thing.
They are not, and this is where the field gets honest about its limits. Vomiting is a brainstem motor reflex. It's a coordinated sequence, and we understand it reasonably well. Nausea is the sensation. It involves cortical regions like the insula and the anterior cingulate. It's an interoceptive experience, a conscious one, and it's much less well understood than the motor act.
Which is why you can stop vomiting and still feel awful for two days.
You've silenced the reflex without touching the experience. That gap is the whole reason Daniel's second flavor of misery exists.
Alright. Mechanism time. Why does blocking D2 receptors in the area postrema actually stop the nausea signal?
Start with what the receptor does when it's stimulated. Dopamine binds D2 in the area postrema, that's a signal to the vomiting center, and the vomiting center coordinates the reflex. Nausea comes along with it. So dopamine is one of the endogenous triggers. It's not the only one, but it's a major one. Now block that receptor with an antagonist, and the endogenous dopamine has nowhere to bind. The trigger is gone.
So the drug isn't suppressing the vomiting center. It's cutting the wire that feeds it.
That's the right picture. And it's why these drugs work so well for nausea that originates from a bloodborne signal, toxins, drugs, metabolic disturbances, rather than from, say, direct irritation of the gut lining.
Metoclopramide. Pramin, as Daniel calls it.
Metoclopramide is a D2 receptor antagonist with prokinetic properties. It's the only FDA-approved medication for gastroparesis in the United States, and it's been that since 1979.
Forty-seven years and still the only one.
Still the only one. That tells you something about how hard it is to develop drugs in this space. Metoclopramide crosses the blood-brain barrier, which is why it has central antiemetic power, and also why it causes central side effects. Fatigue, restlessness, akathisia, and rarely extrapyramidal symptoms.
And sulpiride?
Sulpiride, and its enantiomer levosulpiride, is a substituted benzamide antipsychotic. It's a D2 and D3 antagonist with a predominantly prokinetic effect at low doses. And here's the part that matches Daniel's observation exactly. It's used in Israel, Japan, Korea, and parts of Europe for functional dyspepsia. It is not routinely used in the US or UK.
So his instinct that this is a regional drug is correct.
Completely correct. And it's not just informal practice. The 2025 Spanish ASENEM and semFYC functional dyspepsia guideline explicitly names levosulpiride as a second-line neuromodulator, especially for patients with early satiety and postprandial fullness predominance.
Which is Daniel's phenotype. Here's the part I find elegant. Both of these drugs do two things at once. They block D2 in the brain, and they block D2 in the gut wall, which is prokinetic. It speeds gastric emptying and improves motility. So if your nausea is coming from a stomach that's sluggish and not emptying, you're treating the cause and the symptom with the same molecule.
That's exactly the "two things with one stone" Daniel described. Metoclopramide also has 5-HT4 agonist activity, which adds to the prokinetic effect. So you've got a central antiemetic action and a peripheral prokinetic action in one drug.
Which raises the Vyvanse puzzle. Daniel takes a dopamine-acting drug every day and has never noticed nausea. Why?
Because direction and location matter more than the neurotransmitter itself. Vyvanse is lisdexamfetamine. It's a dopamine agonist and releaser. It increases dopamine signaling. But it does so primarily in the mesolimbic and mesocortical pathways. Reward, focus, executive function. Not the area postrema.
Different neighborhood.
Different neighborhood entirely. The area postrema's D2 receptors trigger nausea when they're stimulated, but amphetamines don't preferentially flood that region at therapeutic doses. There is a pro-emetic threshold, and at ADHD dosing you don't reach it.
But you can.
You absolutely can. High-dose stimulant toxicity causes nausea and vomiting. It's dose-dependent. That's the same mechanism, just pushed hard enough to hit the area postrema.
So the answer to Daniel's puzzle is that Vyvanse and metoclopramide both touch dopamine, but one increases signaling in regions unrelated to the CTZ, and the other blocks signaling specifically at the CTZ.
Same neurotransmitter, different receptor, different location, different direction. And there's one more layer. Amphetamines are indirect agonists. They cause the release of endogenous dopamine. Antiemetics are direct antagonists at the receptor. The pharmacology is opposite in direction.
So it's not even the same kind of interaction with the same molecule.
Not remotely.
That's the mechanism. But the same D2 blockade that stops nausea in the area postrema also hits D2 receptors elsewhere in the brain, and that's where the side effects come from.
This is the part that explains Daniel's next-day fatigue, and it's worth being precise about the receptor families. There are five dopamine receptor subtypes, split into two families. D1-like, which is D1 and D5, and they signal through Gs, so they're stimulatory. And D2-like, which is D2, D3, and D4, and they signal through Gi, so they're inhibitory.
D2 is the antiemetic target.
D2 is the main one. It's found in the brain, in the area postrema, the striatum, the pituitary, and in the periphery, in gut smooth muscle where it modulates motility. D3 receptors are concentrated in limbic regions and are increasingly recognized as important antiemetic targets. Amisulpride is a selective D2 and D3 antagonist, and that selectivity matters.
And the brain versus body distinction is the whole game here.
It's the whole game. Domperidone blocks peripheral D2 receptors but barely crosses the blood-brain barrier. So it avoids the central side effects. No significant fatigue, no extrapyramidal symptoms. That makes it much safer for long-term use.
And metoclopramide does the opposite.
Metoclopramide crosses into the brain. That gives it more central antiemetic power, and it also gives it more central side effects. Same receptor, different address, different risk profile.
So why are these contraindicated for long-term use? What's actually accumulating?
Chronic D2 blockade in the brain's motor circuits causes tardive dyskinesia and extrapyramidal symptoms. Tardive dyskinesia is a potentially irreversible movement disorder. Involuntary facial and oral movements. In 2009, the FDA issued a black box warning on metoclopramide for exactly this risk, with long-term or high-dose use.
How common is it?
Older guidelines suggested one to ten percent. A 2010 review by Rao and Camilleri estimated the actual risk is likely under one percent, and may represent an idiosyncratic or pharmacogenetic response. There's a DRD3 Ser9Gly polymorphism that's been implicated.
So the black box is real but the number is smaller than the label implies.
Smaller than the label implies, and probably concentrated in people with a specific genetic vulnerability. Which is a hard thing to communicate, because the warning has to cover everyone.
Then there's Daniel's fatigue.
Next-day fatigue is a common central side effect of D2 antagonists. It's related to their action on arousal and motivation pathways. Dopamine is doing work in those circuits, and blocking it there produces sedation. Plus there's off-target receptor binding, particularly histaminergic and muscarinic, that adds to the sedation.
So the same drug that cuts the nausea wire also dims the arousal wire.
And you can't separate them with a molecule that crosses the blood-brain barrier indiscriminately. That's the trade-off baked into the pharmacology.
What else is on the risk list?
Hyperprolactinemia. D2 blockade in the pituitary disinhibits prolactin release. That causes galactorrhea, gynecomastia, sexual dysfunction. QT prolongation, especially with sulpiride, which has a real cardiac risk. And drug-induced parkinsonism, which is the motor side of the same coin as tardive dyskinesia.
That's a serious list for a drug people take for an upset stomach.
It is. And it's why the duration and the dose matter so much, and why the long-term contraindication exists.
Which brings us to the question Daniel actually asked. Are there drugs that avoid this trade-off?
The closest existing answer is domperidone. It's a peripheral D2 antagonist that doesn't cross the blood-brain barrier. So you get the antiemetic and prokinetic effect without the central side effects. No significant tardive dyskinesia risk, no next-day fatigue.
That sounds like exactly what Daniel wants.
It's close, with one caveat. Domperidone carries a cardiac QT risk at high intravenous doses. So it's not free. It's just a different risk profile, and for chronic use the trade is usually worth it.
What about amisulpride?
Amisulpride is a selective D2 and D3 antagonist, and it's been approved for intravenous use in post-operative nausea and vomiting. A 2026 randomized trial in neurosurgery patients found intravenous amisulpride at five milligrams was non-inferior to ondansetron at four milligrams for preventing post-operative nausea and vomiting.
Non-inferior to ondansetron is a real result.
It's a real result. And amisulpride is better tolerated than the older antipsychotics at antiemetic doses. It's not a clean answer to the fatigue problem, but it's a step.
Then there's the non-dopaminergic route.
Tradipitant. It blocks substance P and the NK1 receptor instead of dopamine. Completely different mechanism, so it sidesteps the dopamine side-effect problem entirely. In a 2021 Phase 2 trial in gastroparesis, it significantly reduced nausea severity and increased nausea-free days.
And the Phase 3?
The larger 2024 Phase 3 trial missed its primary endpoint in the intention-to-treat population.
Ouch.
It did. But the post-hoc exposure-response analysis showed significant benefit in patients with high blood levels. So the signal is there, it's just not clean enough yet for approval.
That's the frustrating shape of this field. Good mechanism, messy trials.
That's exactly the shape of it. And then there's olanzapine, which is a multi-receptor antipsychotic. D2, 5-HT2, H1, muscarinic. It's now recommended as part of a four-drug regimen for highly emetogenic chemotherapy, and it's described as the most effective agent to prevent chemotherapy-induced nausea. It's used off-label at low doses for refractory nausea, but it carries metabolic and sedating side effects.
So the most effective agent is also the one with the heaviest baggage.
Every time. That's the pattern in this whole class.
What about the newer prokinetics for functional dyspepsia specifically?
Itopride has a dual mechanism. D2 antagonism plus acetylcholinesterase inhibition. It's being studied in the 2026 VIVA trial, vonoprazan with and without itopride. Cinitapride is a fourth-generation prokinetic, a 5-HT4 agonist plus a D2 antagonist, and a 2026 study showed eight-week therapy improves symptom remission in functional dyspepsia. Acotiamide, also called DA-9701, is in Phase IV trials for functional dyspepsia.
So there's a pipeline.
There's a pipeline, and it's slow. Which brings us back to Daniel's frustration, and it's well-founded. The treatment landscape for functional dyspepsia is limited. First-line is H. Pylori eradication if you're positive, then proton pump inhibitors and prokinetics. Second-line is neuromodulators. Tricyclic antidepressants like nortriptyline and amitriptyline, atypical antipsychotics like levosulpiride, and mirtazapine.
Those are all borrowed from psychiatry.
All of them. A 2026 multicenter randomized controlled trial of nortriptyline and a 2026 meta-analysis of mirtazapine both address this space. The field is using psychiatric drugs at low doses because it doesn't have dedicated drugs for this condition.
Which is exactly what Daniel said. Spotty and partial.
Spotty and partial is the correct description. And the emerging non-dopaminergic options, NK1 antagonists, 5-HT3 antagonists, multi-receptor agents like olanzapine, offer efficacy without the dopamine side-effect burden. But tradipitant's Phase 3 miss shows this is still an evolving field. The perfect drug for functional dyspepsia nausea doesn't exist yet.
Before we wrap up, there's one more thing worth sitting with.
Hilbert: Thirty-seven prescriptions for Pramin in one afternoon.
That's a lot for one afternoon.
Hilbert: Small clinic, Haredi neighborhood. I was a pharmacy technician there. Most of the scripts were Pramin, and most of the patients were women with large families. The doctors cycled through the same handful of medications. Metoclopramide, then domperidone, then back to metoclopramide. What stuck with me wasn't the drug. It was the conversations. People came back again and again because the nausea wouldn't quit. Same complaint, same waiting room, different week.
The cycling is the part that interests me. That's what you do when nothing works well and everything works a little.
Hilbert: One day a prescription came through for sulpiride at a dose so low it was below any psychiatric threshold. I asked the pharmacist about it. He said, "That's for the stomach, not the head." I've thought about that sentence for years.
Stomach versus head.
Hilbert: The clinic had a running joke about the Pramin shuffle. Patients would come in, get the prescription, feel better for a few days, then come back with the same complaint. Nobody thought it was strange. It was just the rhythm of the place.
And the distinction the pharmacist drew, stomach versus head, is the one we've been circling all episode. The area postrema is in the brain but outside the blood-brain barrier. So a drug can be "for the stomach" in one context and "for the head" in another, and both descriptions can be true of the same molecule.
Hilbert: I never had a conclusion about it. I just always found it odd that nobody seemed to think it was odd.
What I keep coming back to is that the pharmacist's sentence is a lay description of the exact pharmacology. Central versus peripheral. He didn't have the vocabulary for the blood-brain barrier, but he had the concept.
Hilbert: Anyway. I've got a load of shelving in the back that needs moving before it gets dark.
If the area postrema is the brain's toxin detector, why is nausea, the sensation, so much harder to treat than vomiting, the reflex?
Because the reflex has a defined circuit and the sensation doesn't. You can cut a wire to stop a reflex. You can't cut a wire to stop a feeling, not cleanly. The insula and anterior cingulate are doing something we don't fully understand yet.
The field is moving toward non-dopaminergic antiemetics. NK1 antagonists, 5-HT3 antagonists, multi-receptor agents. But the perfect drug for functional dyspepsia nausea doesn't exist yet.
It doesn't. And Daniel's experience with sulpiride is a perfect illustration of the trade-offs baked into this pharmacology. Effective for nausea, useless for bloating, brutal next-day fatigue. That's not a failure of the drug. That's the anatomy.
If you found this interesting, subscribe and leave a review. And one more time, nothing here is medical advice. If you're struggling with persistent nausea, get medically evaluated.
Thanks as always to our producer, Hilbert Flumingtop.
This has been My Weird Prompts. Email us at show at my weird prompts dot com.
We'll be back soon.
